Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Concomitant RotaTeq and DTP-IPV in Japanese Infants
NCT01926015Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2013
- Primary completion
- Jun 2014
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
01
Overview
A Phase 4 trial of rotavirus vaccine, live, oral, pentavalent in rotavirus infection, sponsored by Merck & Co.. Started Sep 2013; status: completed.
02
Drugs
rotavirus vaccine, live, oral, pentavalent
03
Conditions
rotavirus infection
Beyond the preview
Go deeper on NCT01926015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01926015.